Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Acceleron Pharma's annualizedGross Profit for the quarter that ended in Sep. 2021 was $136.8 Mil.
Acceleron Pharma's average Total Assets over the quarter that ended in Sep. 2021 was $812.0 Mil. Therefore, Acceleron Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2021 was 16.85%.
Acceleron Pharma Gross-Profit-to-Asset % Historical Data
The historical data trend for Acceleron Pharma's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Acceleron Pharma's Gross-Profit-to-Asset %
For the Biotechnology subindustry, Acceleron Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acceleron Pharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acceleron Pharma's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Acceleron Pharma's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Sep. 2021) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Acceleron Pharma Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Acceleron Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Acceleron Pharma (Acceleron Pharma) Business Description
Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XLRN has been successfully added to your 